4//SEC Filing
O'Neill Gilmore Neil 4
Accession 0001650664-24-000015
CIK 0001650664other
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 8:00 PM ET
Size
13.1 KB
Accession
0001650664-24-000015
Insider Transaction Report
Form 4
O'Neill Gilmore Neil
DirectorCEO
Transactions
- Award
Common Stock
2024-03-02+130,700→ 260,869 total - Award
Common Stock
2024-03-02+72,213→ 333,082 total - Award
Common Stock
2024-03-02+72,212→ 405,294 total - Sale
Common Stock
2024-03-05$9.42/sh−77,824$732,884→ 327,470 total - Award
Stock Option (right to buy)
2024-03-02+392,100→ 392,100 totalExercise: $10.53Exp: 2034-03-01→ Common Stock (392,100 underlying)
Footnotes (6)
- [F1]The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028.
- [F2]Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2022.
- [F3]Reflects the vesting, upon the achievement of a business development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2022.
- [F4]Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2024. The sale does not represent a discretionary trade by the Reporting Person.
- [F5]This transaction was executed in multiple trades at prices ranging from $9.1036 to $9.4298. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
- [F6]This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028.
Documents
Issuer
Editas Medicine, Inc.
CIK 0001650664
Entity typeother
Related Parties
1- filerCIK 0001742084
Filing Metadata
- Form type
- 4
- Filed
- Mar 4, 7:00 PM ET
- Accepted
- Mar 5, 8:00 PM ET
- Size
- 13.1 KB